NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.70 -0.93 (-1.13%) GOLD FUTURES
2,302.90 -54.80 (-2.32%) DOW
37,971.53 -414.56 (-1.08%) Bitcoin GBP
48,145.95 -1,973.85 (-3.94%)
AZN Apr 2024 65.000 put
| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 65.00 |
| Expiry date | 2024-04-26 |
| Day's range | 0.0100 - 0.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | 417 |
Insider MonkeyAstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.03 EPS, expectations were $1.22. AstraZeneca PLC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning to those joining […]
BenzingaAstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
European pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury in numerous cases. Lawyers representing the plaintiffs argue that the vaccine resulted in side effects for a small number of families, including brain injuries and fatalities. AstraZeneca, while contesting the claims, has acknowledged in court documents that its vaccine can, in rare instances, cause Thro
Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
WILMINGTON, Del., April 29, 2024--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.
